MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Oligomeric and phosphorylated alpha-synuclein as potential CSF biomarkers for Parkinson’s disease

N.K. Majbour, N.N. Vaikath, K.D. Dijk, M. Ardah, C.E. Teunissen, H.W. Berendse, W.D.J. Berg, O.M.A. El-Agnaf (Amsterdam, Netherlands)

Meeting: 2016 International Congress

Abstract Number: 1916

Keywords: Aging, Parkinsonism

Session Information

Date: Thursday, June 23, 2016

Session Title: Parkinson's disease: Clinical trials, pharmacology and treatment

Session Time: 12:00pm-1:30pm

Location: Exhibit Hall located in Hall B, Level 2

Objective: To explore the potential use of alpha-synuclein (α-syn) species as candidate biomarkers for Parkinson’s disease (PD).

Background: Despite decades of intensive research, to date, there is no accepted diagnosis for PD based on biochemical analysis of blood or CSF. However, neurodegeneration in the brains of PD patients begins several years before the manifestation of the clinical symptoms, pointing to serious flaw/limitations in this approach.

Methods: We generated specific antibodies directed against wide array of α-syn species, namely total-, oligomeric- and phosphorylated-Ser129-α-syn (t-, o- and p-S129-α-syn). Next we employed our antibodies to develop highly specific ELISA assays to quantify α-syn species in biological samples. Finally we verified the usefulness of our assays in CSF samples from 46 PD patients and 48 age-matched healthy controls. We also assessed the discriminating power of combining multiple CSF α-syn species with classical Alzheimer’s disease biomarkers.

Results: The combination of CSF o-/t-α-syn, p-S129-α-syn and p-tau provided the best fitting predictive model for discriminating PD patients from controls. Moreover, CSF o-α-syn levels correlated significantly with the severity of PD motor symptoms (r = -0.37), whereas CSF t-α-syn correlated inversely with MMSE scores (r = -0.46).

Conclusions: Our new ELISA assays can serve as research tools to address the unmet need for reliable CSF biomarkers for PD and related disorders.

To cite this abstract in AMA style:

N.K. Majbour, N.N. Vaikath, K.D. Dijk, M. Ardah, C.E. Teunissen, H.W. Berendse, W.D.J. Berg, O.M.A. El-Agnaf. Oligomeric and phosphorylated alpha-synuclein as potential CSF biomarkers for Parkinson’s disease [abstract]. Mov Disord. 2016; 31 (suppl 2). https://www.mdsabstracts.org/abstract/oligomeric-and-phosphorylated-alpha-synuclein-as-potential-csf-biomarkers-for-parkinsons-disease/. Accessed May 18, 2025.
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2016 International Congress

MDS Abstracts - https://www.mdsabstracts.org/abstract/oligomeric-and-phosphorylated-alpha-synuclein-as-potential-csf-biomarkers-for-parkinsons-disease/

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
      • Welcome to the MDS Abstracts Site
      • Effect of marijuana on Essential Tremor: A case report
      • Advanced Search
      • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
      • Covid vaccine induced parkinsonism and cognitive dysfunction
      • Help & Support
      • About Us
      • Cookies & Privacy
      • Wiley Job Network
      • Terms & Conditions
      • Advertisers & Agents
      Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
      Wiley